Navigation Links
Pharmac Blamed Of Depriving People of Lifesaving Drug

Two cardiologists accuse Pharmac of not properly funding the cholesterol lowering drugs to the new Zealanders. They published the report in the New Zealand medical //journal which they point out the shortsighted approach of the agency toward important drugs.

Cardiologists Dr Chris Ellis and Dr Harvey White said that the agency did not allocate funds for the statins for a period of 20 years.

Statins are drugs which help in the reduction of cholesterol levels and prevent heart problems such as heart attacks and strokes.

Pharmac's policies have limited the access of statins to the patients who were in dire need of the drug. This has increased the number of people suffering from heart problems due to inaccessibility of the drug. Hence the cardiologists accuse the agency of patient neglect and public deceit.

The statins are very efficient in lowering the cholesterol levels by about 58%. The initial clinical trails conducted during1986 is a proof for the efficiency of the drug. Despite of its efficiency the drug was not made widely available to patients in New Zealand until 1997. After which only statins which showed no mortality and low beneficial outcomes were funded by the agency.

The report by the cardiologist therefore blames Pharmac for misrepresenting scientific data, ignoring evidence based medicine and restricting access to medicine with the help of bureaucratic hurdles. This has resulted in more harm and premature death to New Zealanders.

National's Associate Health spokeswoman Jackie Blue said that the agency would have to alter its funding policy for the welfare of the people and also to attract more pharmaceutical companies.


Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Medicis Pharmaceutical company enters pediatric market
4. Pharmacies in for a dose of bitter medicine
5. Pharmacia may take 51.5 percent Abbott stake
6. Pharmaceutical companies are targeting patients
7. FDA approves Watson Pharmaceuticals Oxytrol patch
8. Pharmacist’s Role in Medication Error
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:

(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: